Item 1.01. Entry into a Material Definitive Agreement.

On April 2, 2020, Thermo Fisher Scientific Inc. (the "Company") issued €600,000,000 aggregate principal amount of 1.750% Senior Notes due 2027 (the "2027 Notes") and €600,000,000 aggregate principal amount of 2.375% Senior Notes due 2032 (the "2032 Notes", and, together with the 2027 Notes, the "Notes") in a public offering (the "Offering") pursuant to a registration statement on Form S-3 (File No. 333-229951) and a preliminary prospectus supplement and prospectus supplement related to the offering of the Notes, each as previously filed with the Securities and Exchange Commission (the "SEC").

The Notes are subject to a Paying Agency Agreement (the "Paying Agency Agreement"), dated as of April 2, 2020, between the Company and The Bank of New York Mellon, London Branch, as paying agent. The Notes were issued under an indenture, dated as of November 20, 2009 (the "Base Indenture"), and the Twenty-First Supplemental Indenture, dated as of April 2, 2020 (the "Supplemental Indenture" and, together with the Base Indenture, the "Indenture"), between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee. The sale of the Notes was made pursuant to the terms of an Underwriting Agreement, which the Company entered into on March 30, 2020 (the "Underwriting Agreement"), with J.P. Morgan Securities plc, Morgan Stanley & Co. International plc, Merrill Lynch International and Citigroup Global Markets Limited as lead managers of the several underwriters named in Schedule A to the Underwriting Agreement.

--------------------------------------------------------------------------------

The 2027 Notes will mature on April 15, 2027, and the 2032 Notes will mature on April 15, 2032. Interest on the Notes will be paid annually in arrears on April 15 of each year, beginning on April 15, 2020.

Prior to February 15, 2027, in the case of the 2027 Notes, and January 15, 2032, in the case of the 2032 Notes (each such date, a "Par Call Date"), the Company may redeem the Notes of any series, in whole at any time or in part from time to time, at a redemption price equal to the greater of (1) 100% of the principal amount of the Notes to be redeemed and (2) the sum of the present values of the remaining scheduled payments of principal and interest in respect of the Notes being redeemed (not including any portion of the payments of interest accrued but unpaid as of the date of redemption and assuming that such notes to be redeemed matured on their applicable Par Call Date), discounted to the date of redemption on an annual basis (ACTUAL/ACTUAL (ICMA)), using a discount rate equal to the Comparable Bond Rate (as defined in the Indenture) plus 40 basis points, in the case of the 2027 Notes, and 45 basis points, in the case of the 2032 Notes, plus, in each case, accrued and unpaid interest on the Notes being redeemed, if any, to, but excluding, the date of redemption.

In addition, on and after the applicable Par Call Date, the Company may redeem some or all of the Notes at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding the date of redemption.

Upon the occurrence of a change of control (as defined in the Indenture) of the Company and a contemporaneous downgrade of the Notes below an investment grade rating by at least two of Moody's Investors Service, Inc., S&P Global Ratings, a division of S&P Global, Inc., and Fitch Ratings Limited, the Company will, in certain circumstances, be required to make an offer to purchase the Notes at a price equal to 101% of the principal amount of the Notes, plus any accrued and unpaid interest, if any, to, but excluding, the date of repurchase.

The Notes are general unsecured obligations of the Company. The Notes rank equally in right of payment with existing and any future unsecured and unsubordinated indebtedness of the Company and rank senior in right of payment to any existing and future indebtedness of the Company that is subordinated to the Notes. The Notes are also effectively subordinated to any existing and future secured indebtedness of the Company to the extent of the assets securing such indebtedness, and are structurally subordinated to all existing and any future indebtedness and any other liabilities of its subsidiaries.

The Indenture contains limited affirmative and negative covenants of the Company. The negative covenants restrict the ability of the Company and its subsidiaries to incur debt secured by liens on Principal Properties (as defined in the Indenture) or on shares of stock of the Company's Principal Subsidiaries (as defined in the Indenture) and engage in sale and lease-back transactions with respect to any Principal Property. The Indenture also limits the ability of the Company to merge or consolidate or sell all or substantially all of its assets.

Upon the occurrence of an event of default under the Indenture, which includes payment defaults, defaults in the performance of affirmative and negative covenants, bankruptcy and insolvency related defaults and failure to pay certain indebtedness, the obligations of the Company under the Notes may be accelerated, in which case the entire principal amount of the Notes would be immediately due and payable.

The Company expects that the net proceeds will be approximately €1.18 billion from the Offering, after deducting underwriting discounts and estimated offering expenses. The Company intends to use the net proceeds of the Offering (together with cash on hand) to pay a portion of the consideration for the previously announced acquisition of QIAGEN N.V., a public limited liability company organized under

--------------------------------------------------------------------------------

the laws of The Netherlands ("QIAGEN"), including the repayment of indebtedness of QIAGEN, and for general corporate purposes, which may include the acquisition of companies or businesses, repayment and refinancing of debt (which may include our Floating 2-Year Senior Notes due August 7, 2020), working capital and capital expenditures or the repurchase of our outstanding equity securities.

Wilmer Cutler Pickering Hale and Dorr LLP, U.S. counsel to the Company, has issued an opinion to the Company, dated April 2, 2020, regarding the Notes. A copy of this opinion is filed as Exhibit 5.1 hereto.

The foregoing description of the Underwriting Agreement and certain of the terms of the Indenture does not purport to be complete and is qualified in its entirety by reference to the full text of each of the Underwriting Agreement, the Base Indenture and the Supplemental Indenture, which are filed with this report as Exhibits 1.1, 4.1 and 4.2 hereto, respectively. Each of the foregoing documents is incorporated herein by reference.

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal


           Year.


(a) Amendment of By-Laws

On March 30, 2020, the Board of Directors of the Company adopted and approved amended and restated By-Laws of the Company. The amendments, which were effective upon adoption by the Board:



     •  clarify the calling and conduct of, and participation in, stockholder
        meetings, including by providing explicit provisions regarding the use of
        remote communication in connection with a meeting (Article I, Sections
        1-4, 7-8 and 12);


     •  revise the stockholder voting standard to default in certain situations to
        the rules and regulations of any stock exchange applicable to the Company,
        or any law or regulation applicable to the Company or its securities
        (Article I, Section 5); and


     •  update and revise the existing provisions regarding notice by stockholders
        of nominations and proposals, including certain information required to be
        provided in such notice (Article I, Section 9).

The amendments to the By-Laws also include procedural, conforming and clarifying changes, including changes to conform to current provisions of the Delaware General Corporation Law, and eliminate provisions that have become obsolete due to the passage of time (Article I, Sections 1-5, 8-9 and 11, Article II, Sections 2-3, 5-6, and 11-12, Article III, Sections 2 and 4, Article IV, Section 1, Article V, Sections 1, 3-4 and 9, Article VI, Sections 2 and 3). The foregoing description of the amendments to the By-Laws is qualified in its entirety by reference to the By-Laws, as amended, a copy of which is attached hereto as Exhibit 3.1 and is incorporated by reference herein.

(b) No change has been made to the Company's fiscal year.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits.

Exhibit
   No.                                       Description

   1.1             Underwriting Agreement, dated March 30, 2020, among the Company,
                 as issuer, and J.P. Morgan Securities plc, Morgan Stanley & Co.
                 International plc, Merrill Lynch International and Citigroup Global
                 Markets Limited and the several other underwriters named in Schedule
                 A of the Underwriting Agreement.

--------------------------------------------------------------------------------



   3.1          Amended and Restated By-Laws of the Registrant, as amended and
              effective as of March 30, 2020.

   4.1          Indenture, dated as of November 20, 2009, between the Company, as
              issuer, and The Bank of New York Mellon Trust Company, N.A., as
              trustee (filed as Exhibit 99.1 to the Registrant's Current Report on
              Form 8-K filed November 20, 2009 [File No. 1-8002] and incorporated in
              this document by reference).

   4.2          Twenty-First Supplemental Indenture, dated as of April 2, 2020,
              between the Company, as issuer, and The Bank of New York Mellon Trust
              Company, N.A., as trustee.

   5.1          Opinion of Wilmer Cutler Pickering Hale and Dorr LLP.

  23.1          Consent of Wilmer Cutler Pickering Hale and Dorr LLP (contained in
              Exhibit 5.1 above).

  104         Cover Page Interactive Data File (embedded with the Inline XBRL
              document).


Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about Thermo Fisher's intended use of proceeds and the proposed QIAGEN acquisition. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in Thermo Fisher's Annual Report on Form 10-K for the year ended December 31, 2019, which is on file with the U.S. Securities and Exchange Commission ("SEC") and available in the "Investors" section of Thermo Fisher's website, ir.thermofisher.com, under the heading "SEC Filings," and in any subsequent Quarterly Reports on Form 10-Q and other documents Thermo Fisher files with the SEC. While Thermo Fisher may elect to update forward-looking statements at some point in the future, Thermo Fisher specifically disclaims any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing Thermo Fisher's views as of any date subsequent to the date of this communication.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses